Loading...
XNAS
ANGO
Market cap464mUSD
Oct 08, Last price  
11.23USD
1D
-20.86%
1Q
-12.20%
Jan 2017
-33.43%
IPO
-20.80%
Name

AngioDynamics Inc

Chart & performance

D1W1MN
XNAS:ANGO chart
P/E
—
P/S
1.45
EPS
—
Div yield, %
—
Shrs. gr., 5y
1.61%
Rev. gr., 5y
1.93%
Revenues
320m
+9.46%
112,227,000166,500,000195,054,000216,035,000215,957,000221,787,000342,026,000354,455,000356,974,000353,690,000349,643,000344,285,000359,484,000264,157,000291,010,000316,219,000338,752,000303,914,000292,498,000320,174,000
Net income
-37m
L+8.09%
-9,127,00010,889,0009,932,00012,312,0008,117,000-5,183,000-1,211,0002,347,000-3,388,000-43,590,000-7,052,00016,335,00061,340,000-166,787,000-31,548,000-26,547,000-52,442,000-184,349,000-33,993,000-36,742,000
CFO
3m
P
8,784,00025,907,00019,942,00039,959,00033,870,00011,602,00026,652,00024,681,00025,685,00045,216,00055,745,00041,287,00037,440,000-14,554,00024,093,000-7,194,00078,000-28,158,000-10,128,0003,089,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

AngioDynamics, Inc. specializes in the development, manufacturing, and commercialization of a diverse array of medical, surgical, and diagnostic instruments. These products are utilized by healthcare professionals to address conditions such as peripheral vascular disease, facilitate vascular access, and support various oncology and surgical interventions, serving both domestic and international markets. The company's portfolio includes advanced ablation systems like NanoKnife, designed for the precise surgical removal of soft tissues, and Solero microwave and radiofrequency systems, effective in ablating solid cancerous or benign growths. Additionally, they provide BioSentry tract sealant systems, IsoLoc Endorectal Balloons, Alatus vaginal balloon packing systems, angiographic catheters, guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits. Their endovascular therapies segment encompasses solutions for thrombus management, atherectomy procedures, core peripheral products, and the treatment of venous insufficiency. Furthermore, AngioDynamics is a key supplier of vascular access devices, such as peripherally inserted central catheters (PICCs), midline catheters, implantable ports, and dialysis catheters, along with associated accessories. These are primarily employed for short-duration systemic drug delivery, including chemotherapy and antibiotics, marketed under a robust portfolio of brand names such as BioFlo, BioFlo Midline, BioFlo PICC, Xcela PICC, PASV, BioFlo Port, SmartPort, Vortex, LifeGuard, BioFlo DuraMax, and DuraMax. The company distributes its offerings directly to a specialized clientele, including interventional radiologists, cardiologists, vascular surgeons, urologists, interventional and surgical oncologists, and critical care nurses, while also leveraging established distributor networks. Founded in 1988, AngioDynamics maintains its corporate headquarters in Latham, New York.

Key people

James C. Clemmer
President, Chief Executive Officer, Director · since 2016
Chief Financial Officer, Executive Vice President, IR Contact Officer · since 2017
Stephen A. Trowbridge
Chief Financial Officer, Executive Vice President, General Counsel · since 2020
Chad T. Campbell
Senior Vice President and General Manager, Vascular Access · since 2016
Benjamin H. Davis
Senior Vice President Business Development · since 2015
David D. Helsel
Senior Vice President - Global Operations · since 2017
Warren G. Nighan
Senior Vice President Quality and Regulatory Affairs · since 2017
Kim L. Seabury
Senior Vice President, Information Technology
Brent J. Boucher
Senior Vice President and General Manager, Oncology/Surgery · since 2017
Eileen O'Shea Auen
Independent Director · since 2016
Howard W. Donnelly
Independent Chairman of the Board · since 2014
Kevin J. Gould
Independent Director · since 2010
Wesley E. Johnson
Independent Director · since 2007
Independent Director · since 2019
Dennis S. Meteny
Independent Director · since 2004
Independent Director · since 2016
IPO date
May 27, 2004
Employees
815
Domiciled in
US
Incorporated in
US
Headquarters & legal address
C/O The Corporation Trust Company
Corporation Trust Center
1209 Orange Street
Wilmington, DE 19801
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2026‑052025‑052024‑052023‑052022‑052021‑052020‑052019‑052018‑052017‑05
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT